The American Journal of Medicine
Volume 120, Issue 4, Supplement 1 , Pages S21-S25 , April 2007

Potential Genetic Causes of Heterogeneity of Treatment Effects

  • David B. Goldstein, PhD

      Affiliations

    • Center for Population Genomics and Pharmacogenetics, Duke Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
    • Corresponding Author InformationRequests for reprints should be addressed to David B. Goldstein, PhD, Center for Population Genomics and Pharmacogenetics, Duke Institute for Genome Sciences and Policy, Duke University, 103 Research Drive, Room 4006 GSRB II, Durham, North Carolina 27710.
    • ,
  • Anna C. Need, PhD

      Affiliations

    • Center for Population Genomics and Pharmacogenetics, Duke Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
    • ,
  • Rinki Singh, MD

      Affiliations

    • Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, London, United Kingdom
    • ,
  • Sanjay M. Sisodiya, MD, PhD

      Affiliations

    • Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, London, United Kingdom

References 

  1. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med. 2001;7:201–204
  2. Greenfield S, Kravitz R, Duan N, Kaplan SH. Heterogeneity of treatment effects: implications for guidelines, payment and quality assessment. Am J Med. 2007;120:S3–S9
  3. Fritz N, Glogau S, Hoffmann J, et al. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav. 2005;6:373–381
  4. Kockelmann E, Elger CE, Helmstaedter C. Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of topiramate in epilepsy patients. Epilepsy Res. 2003;54:171–178
  5. Lee S, Sziklas V, Andermann F, et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia. 2003;44:339–347
  6. Rorsman I, Kallen K. Recovery of cognitive and emotional functioning following withdrawal of topiramate maintenance therapy. Seizure. 2001;10:592–595
  7. Thompson PJ, Baxendale SA, Duncan JS, Sander JW. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry. 2000;69:636–641
  8. Han SW, Kim TY, Jeon YK, et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res. 2006;12:2538–2544
  9. Hamelin BA, Turgeon J, Vallee F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther. 1996;60:512–521
  10. Ereshefsky L, Riesenman C, Lam YW. Antidepressant drug interactions and the cytochrome P450 system: the role of cytochrome P450 2D6. Clin Pharmacokinet. 1995;29(suppl 1):10–18
  11. Brosen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Investig. 1993;71:1002–1009
  12. Eap CB, Bondolfi G, Zullino D, et al. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol. 2001;21:330–334
  13. Whyte EM, Romkes M, Mulsant BH, et al. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. Int J Geriatr Psychiatry. 2006;21:746–751
  14. Steimer W, Zopf K, von Amelunxen S, et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem. 2004;50:1623–1633
  15. Steimer W, Zopf K, von Amelunxen S, et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem. 2005;51:376–385
  16. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6–13
  17. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442–473
  18. Rogowski W. Current impact of gene technology on healthcare: a map of economic assessments. Health Policy. 2007;80:340–357
  19. Need AC, Motulsky AG, Goldstein DB. Priorities and standards in pharmacogenetic research. Nat Genet. 2005;37:671–681
  20. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229–243
  21. Johansson I, Oscarson M, Yue QY, et al. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol. 1994;46:452–459
  22. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol. 1996;42:713–719
  23. Tate SK, Goldstein DB. Will tomorrow’s medicines work for everyone?. Nat Genet. 2004;36(suppl):S34–S42
  24. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res. 2006;83:185–192
  25. Bertolino A, Caforio G, Blasi G, et al. Interaction of COMT (Val108/158 Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry. 2004;161:1798–1805
  26. Hedenmalm K, Guzey C, Dahl ML, Yue QY, Spigset O. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol. 2006;26:192–197
  27. Matsumoto C, Shinkai T, De Luca V, et al. Association between three functional polymorphisms of the dopamine D2 receptor gene and polydipsia in schizophrenia. Int J Neuropsychopharmacol. 2005;8:245–253
  28. Zhao AL, Zhao JP, Zhang YH, et al. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci. 2005;115:1539–1547
  29. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet. 1997;6:577–582
  30. Contini V, Marques FZ, Garcia CE, Hutz MH, Bau CH. MAOA-uVNTR polymorphism in a Brazilian sample: further support for the association with impulsive behaviors and alcohol dependence. Am J Med Genet B Neuropsychiatr Genet. 2006;141:305–308
  31. Garpenstrand H, Ekblom J, Forslund K, Rylander G, Oreland L. Platelet monoamine oxidase activity is related to MAOB intron 13 genotype. J Neural Transm. 2000;107:523–530
  32. Heinz A, Goldman D, Jones DW, et al. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology. 2000;22:133–139
  33. Syvanen AC, Tilgmann C, Rinne J, Ulmanen I. Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics. 1997;7:65–71
  34. Wei J, Ramchand CN, Hemmings GP. Possible association of catecholamine turnover with the polymorphic (TCAT)n repeat in the first intron of the human tyrosine hydroxylase gene. Life Sci. 1997;61:1341–1347
  35. Need AC, Ahmadi KR, Spector TD, Goldstein DB. Obesity is associated with genetic variants that alter dopamine availability. Ann Hum Genet. 2006;70:293–303
  36. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106:2329–2333
  37. Ahmadi KR, Weale ME, Xue ZY, et al. A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet. 2005;37:84–89
  38. Shah PR, hmad-Annuar A, Ahmadi KR, et al. No association of DYNC1H1 with sporadic ALS in a case-control study of a northern European derived population: a tagging SNP approach. Amyotroph Lateral Scler Other Motor Neuron Disord. 2006;7:46–56
  39. Shephard N, John S, Cardon L, McCarthy MI, Zeggini E. Will the real disease gene please stand up?. BMC Genet. 2005;6(suppl 1):S66

PII: S0002-9343(07)00137-4

doi: 10.1016/j.amjmed.2007.02.004

The American Journal of Medicine
Volume 120, Issue 4, Supplement 1 , Pages S21-S25 , April 2007

Article Tools